Last reviewed · How we verify

NCT05851287: AECS

The Aging Eye Cohort Study

Recruiting now Last updated 9 May 2023
What this trial tests

trial in Eye Diseases in 2,500 participants. Currently enrolling.

Timeline
20 February 2023
Primary endpoint
19 February 2028
19 February 2029

Quick facts

Lead sponsorZhongshan Ophthalmic Center, Sun Yat-sen University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,500
Start date20 February 2023
Primary completion19 February 2028
Estimated completion19 February 2029
Sites1 location across China

Conditions studied

Sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Who can join

Adults 60 to 95, any sex, with Eye Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aging is a major risk factor for many blind-causing eye diseases, e.g., glaucoma, age-related cataracts, and age-related macular degeneration. With the population aging, the impact of lifestyle changes (less time spent outdoors, increasingly sedentary lifestyles, and unhealthy eating habits) on the eye health of the elderly needs further research. This study focuses on establishing a cohort of elderly subjects with normal vision and ocular structure at baseline. The main goal is to study the risk factors for common eye diseases in Chinese elderly population while providing normal-controlled clinical and genomic data for other clinical studies on eye diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Eye Diseases

Currently open trials in the same condition.

Other Zhongshan Ophthalmic Center, Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05851287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing